ENTA
NASDAQEnanta Pharmaceuticals Inc.
Price$11.26-0.23 (-2.00%)
01:30 PM07:45 PM
News · 26 weeks38-80%
2025-12-142026-06-07
Mix1990d
- Insider6(32%)
- Other6(32%)
- SEC Filings5(26%)
- Analyst1(5%)
- Earnings1(5%)
Latest news
25 items- PREnanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be
- SECSEC Form S-8 filed by Enanta Pharmaceuticals Inc.S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECSEC Form 10-Q filed by Enanta Pharmaceuticals Inc.10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV) On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026 Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clin
- PREnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Florida. Details of the presentations are as follows: Title: Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial Abstract Number: 12336 Session C96:
- PREnanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of UrticariaPhase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyn
- PREnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025 in Munich, Germany. The first oral presentation will include results from RSVHR, the Phase 2b study of zelicapavir in high-risk adults, which were announced in September 2025, showing about a week improvement in complete symptom r
- PREnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company's STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA. Details of the presentations are as follows: Poster Number: 573 Abstract Number: 2257506 Title: Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities Date: Thursday, April 16, 2026 Ti
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.SCHEDULE 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
- ANALYSTRodman & Renshaw initiated coverage on Enanta Pharmaceuticals with a new price targetRodman & Renshaw initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $20.00
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- INSIDERSEC Form 4 filed by Director Vance Terry4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Russell Lesley4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Peterson Kristine4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Hata Yujiro S4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Foletta Mark G4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Carter Bruce L A4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals to Present at The Citizens Life Sciences ConferenceEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, c
- SECSEC Form EFFECT filed by Enanta Pharmaceuticals Inc.EFFECT - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- INSIDERChief Legal Officer Kowalsky Matthew Paul was granted 5,493 shares and covered exercise/tax liability with 1,902 shares (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERChief Business Officer Luu Brendan covered exercise/tax liability with 3,257 shares and was granted 6,562 shares, increasing direct ownership by 9% to 41,634 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERChief Product Strategy Officer Kieffer Tara Lynn was granted 6,562 shares and covered exercise/tax liability with 3,257 shares, increasing direct ownership by 11% to 33,925 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERChief Medical Officer Rottinghaus Scott T. was granted 6,875 shares and covered exercise/tax liability with 3,413 shares, increasing direct ownership by 16% to 25,254 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
ENTA FAQ
7 questionsWhat does Enanta Pharmaceuticals Inc. do?
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize...Where does ENTA stock trade?
Enanta Pharmaceuticals Inc. (ENTA) is listed on NASDAQ.What sector and industry is ENTA in?
Enanta Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enanta Pharmaceuticals Inc. go public?
Enanta Pharmaceuticals Inc. (ENTA) completed its IPO in 2013.What are analysts saying about ENTA?
Enanta Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $2000.00 price target on 2026-03-26. Recent price targets range from $1400.00 to $2000.00.What companies are similar to ENTA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ENTA side-by-side with any of them on Quantisnow.How can I track ENTA on Quantisnow?
Quantisnow aggregates Enanta Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENTA to receive live email and push alerts on every new disclosure.